Maforan 5 mg Tablet

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

Warfarin Sodium Clathrate

Boleh didapati daripada:

GoodScience Sdn. Bhd.

INN (Nama Antarabangsa):

Warfarin Sodium Clathrate

Unit dalam pakej:

10 x 10 Tablets

Dikeluarkan oleh:

Sriprasit Pharma Co. Ltd.

Risalah maklumat

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
MAFORAN TABLET
Warfarin Sodium (as Warfarin Sodium Clathrate) (1 mg, 2 mg, 5 mg)
_ _
1
WHAT IS IN THIS LEAFLET
1.
What Maforan is used for
2.
How Maforan works
3.
Before you use Maforan
4.
How to use Maforan
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of Maforan
8.
Product Description
9.
Manufacturer
and Product Registration
Holder
10.
Date of Revision
WHAT MAFORAN IS USED FOR
Maforan is used to prevent and/or to treat
blood clots forming in blood vessels. It helps
to reduce the tendency of blood to form clots
in
the
legs,
lungs,
brain
or
heart,
and
to
prevent formation or reoccurrence of blood
clots after heart attack.
HOW MAFORAN WORKS
Maforan
contains
warfarin
sodium
that
belongs
to
a
group
of
medicines
called
anticoagulants. It increases the times it takes
for your blood to clot and prevent excessive
clotting.
BEFORE YOU USE MAFORAN
-
_When you must not use it_
Do not use Maforan if you:
•
are
allergic
to
warfarin
sodium,
or
any
ingredients in this medication.
• are pregnant or plan for a pregnancy.
• have a bleeding tendency or bruise easily.
•
have any scheduled operations/surgeries,
even minor.
•
have
high
blood
pressure
that
is
not
controlled by medicines.
• suffer from severe liver insufficiency or
liver cirrhosis.
• have certain conditions such as:
- stomach or intestinal bleeding or ulcers;
- bleeding in the lungs or kidneys, bladder or
urethra;
-
cerebral
haemorrhage
(bleeding
in
the
brain);
- heart infection;
- swelling of the heart membrane or fluid in
the heart;
- brain aneurysm (swelling of an artery that
supplies blood to the brain).
• have tendency to fall due to neurological or
other health-related conditions.
• have dementia, psychoses, alcoholism or
another
situation
where
the
anticoagulant
treatment cannot be administrated safely.
• are taking medicines that may increase your
risk of bleeding or other medicines that stop
the blood from clotting.
• have a physical condition which might have
a risk of

Ciri produk

COMPOSITION
Each MAFORAN 1 MG, 2 MG, 3 MG, 4 MG and 5 MG TABLET contains
Warfarin Sodium 1 mg, 2 mg, 3 mg, 4 mg and 5 mg (as Warfarin Sodium
Clathrate) respectively.
DESCRIPTION
MAFORAN 1 MG TABLET: White flat round tablet with a bisect and
debossed
with “MAFORAN”, “1” on one side, plain on the other.
MAFORAN 2 MG TABLET: Orange flat round tablet with a bisect and
debossed with “MAFORAN”, “2” on one side, plain on the other.
MAFORAN 3 MG TABLET: Dark blue flat round tablet with a bisect and
debossed with “MAFORAN”, “3” on one side, plain on the other.
MAFORAN 4 MG TABLET: Yellow flat round tablet with a bisect and
debossed with “MAFORAN”, “4” on one side, plain on the other.
MAFORAN 5 MG TABLET: Pink flat round tablet with a bisect and debossed
with “MAFORAN”, “5” on one side, plain on the other.
PHARMACODYNAMICS
Warfarin or 4-hydroxycoumarin is an anticoagulant that acts by
inhibiting
the synthesis of vitamin K-dependent clotting factors II, VII, IX and
X, and
the
anticoagulant
proteins
C
and
S.
Of
its
isomers,
S-warfarin
is
approximately 5 times as potent an anticoagulant as R-warfarin.
Vitamin K is an essential cofactor for the post ribosomal synthesis of
the
vitamin K-dependent clotting factors. Vitamin K promotes the
biosynthesis
RI Ȗ-carboxyglutamic acid residues in the proteins that are
essential for
biological activity. Warfarin is thought to interfere with clotting
factor
synthesis by inhibition of the C1 subunit of vitamin K epoxide
reductase
(VKORC1) enzyme complex, thereby reducing the regeneration of vitamin
K1 epoxide. The degree of depression is dependent upon the dosage
administered. Therapeutic doses of warfarin decrease the total amount
of
the active form of each vitamin K dependent clotting factor made by
the
liver by approximately 30% to 50%.
An anticoagulation effect generally occurs within 24 hours after drug
administration. However, peak coagulant effect may be delayed 72 to 96
hours. The duration of action of a single dose of racemic warfarin is
2